Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.

Ader, Florence; Bouscambert-Duchamp, Maude; Hites, Maya; Peiffer-Smadja, Nathan; Mentré, France; Burdet, Charles; DisCoVeRy Study Group; Belkhir, Leïla

doi:10.1016/S1473-3099(22)00295-X

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.

Ader, Florence

;

Bouscambert-Duchamp, Maude

;

Hites, Maya

;

Peiffer-Smadja, Nathan

;

Belkhir, Leïla

;et.al.

(2022) The Lancet Infectious Diseases — Vol. 22, n° 6, p. 764-765 (2022)

Files

2022_Ader_Lancet_Infect_Dis.pdf

Open Access
Adobe PDF
729.07 KB

Download

Details

Authors

Ader, Florence
Author
Bouscambert-Duchamp, Maude
Author
Hites, Maya
Author
Peiffer-Smadja, Nathan
Author
Belkhir, LeïlaUCLouvain
Collaborator

Affiliations

UCLouvainSSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology
UCLouvain(SLuc) Service de médecine interne et maladies infectieuses (MIMI)

Citations

APA
Chicago
FWB

Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Mentré, F., & Burdet, C. (2022). Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. The Lancet Infectious Diseases, 22(6), 764-765. https://doi.org/10.1016/S1473-3099(22)00295-X (Original work published 2022)